Upcoming Investor Conferences Highlight Ascentage Pharma's Innovations

Ascentage Pharma’s Engagement in Upcoming Investor Conferences
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) continues to stand at the forefront of biopharmaceutical innovation. This September, the company is gearing up for an integral presence in the investor community by participating in three pivotal investor conferences. These events showcase Ascentage Pharma's commitment to advancing novel therapies to meet critical medical needs in the realm of cancer treatment.
Key Conferences and Presentations
Ascentage Pharma's management team will take part in a series of discussions designed to elaborate on the company's mission and developments:
Citi's 2025 Biopharma Back to School
This conference is scheduled for September 3, where a fireside chat at 4:00 pm EDT will unfold. Attendees will gain insights into the innovative strategies Oncentage Pharma is employing in the healthcare landscape.
Cantor Global Healthcare Conference 2025
On September 4, a fireside chat will be held at 2:45 pm EDT. This will serve as another platform for Ascentage Pharma to highlight its focus on addressing significant therapeutic gaps in cancer care.
H.C. Wainwright 27th Annual Global Investment Conference
The company will conclude its conference participation with a presentation on September 10 at 1:30 pm EDT. This event is crucial for engaging potential investors and cultivating partnerships for future innovation.
About Ascentage Pharma Group International
Ascentage Pharma is recognized as a global, integrated biopharmaceutical company dedicated to discovering and developing cutting-edge therapies aimed at unmet medical needs in oncology. The firm has developed a promising portfolio rich in innovative drug products, focusing on inhibitors that target critical proteins essential to the apoptotic pathway, including Bcl-2 and MDM2-p53, along with next-generation kinase inhibitors.
Innovative Treatment Solutions and Pipeline Development
The company’s flagship product, Olverembatinib, marks a significant milestone as the first third-generation BCR-ABL1 inhibitor. Approved for treating patients with chronic myeloid leukemia (CML), it stands out for its efficacy against T315I mutations. This drug is included in the China National Reimbursement Drug List (NRDL), enhancing accessibility for patients. In addition, Ascentage Pharma is undertaking an FDA-cleared registrational Phase III trial for Olverembatinib, aimed at further solidifying its effectiveness across various patient demographics.
Additionally, Lisaftoclax, Ascentage Pharma's second approved drug, serves as a novel Bcl-2 inhibitor intended for various hematologic malignancies. Its approval by China’s National Medical Products Administration (NMPA) to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients provides a crucial new option, particularly for those who have undergone previous treatment regimens.
Global Collaborations and Future Directions
Ascentage Pharma's reach extends through strategic partnerships with industry leaders like Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with premier research institutions. This vast network aids in enhancing their research and development initiatives, further pushing the boundaries of cancer therapy.
Contact Information for Inquiries
For those seeking further information on Ascentage Pharma's conference participations or product details, the following contact points are provided:
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Jon Yu
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 677-1855
Frequently Asked Questions
What is Ascentage Pharma's core focus?
Ascentage Pharma is dedicated to developing innovative therapies for cancer treatment, addressing critical unmet medical needs.
When are the upcoming investor conferences?
Ascentage Pharma will participate in key conferences on September 3, 4, and 10 of this year.
What products has Ascentage Pharma developed?
The company has developed significant therapies like Olverembatinib and Lisaftoclax, targeting various cancers.
How can investors learn more about Ascentage Pharma?
Investors can access information at Ascentage Pharma’s investor relations section on their website.
Who should be contacted for investor inquiries?
For investor relations, Hogan Wan and Stephanie Carrington are key contacts at Ascentage Pharma and ICR Healthcare, respectively.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.